GlassScriptPhysician profile
Kyle Moody Adams
NPI 1508284431
$3,729.59
in general payments reported to CMS, 2019-2025
31 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $756 · 2020: $800 · 2021: $1,495 · 2022: $580 · 2023: $34.78 · 2024: $63.78.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $98.56.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $98.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $730.57 | 2019-2024 | Qulipta |
| Novo Nordisk INC | $442.23 | 2019-2022 | |
| Amgen INC. | $292.13 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $204.65 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $198.78 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $168.61 | 2019-2022 | |
| Pfizer INC. | $156.13 | 2019-2024 | |
| Lilly USA, LLC | $155.21 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $128.93 | 2021 | |
| Astellas Pharma US INC | $125.07 | 2020-2021 | |
| Gilead Sciences, INC. | $124.85 | 2019 | |
| Allergan, INC. | $108.54 | 2019-2021 | |
| Amarin Pharma, INC. | $108.26 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $107.16 | 2020-2022 | |
| Teva Pharmaceuticals USA, INC. | $94.73 | 2020-2021 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $87.34 | 2020-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $85.99 | 2019-2021 | |
| Eisai INC. | $60.18 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $58.23 | 2022 | |
| Dexcom, INC. | $50.68 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $34.74 | 2019-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $33.40 | 2022 | |
| Bausch Health US, LLC | $30.66 | 2020-2021 | |
| Esperion Therapeutics, INC. | $28.37 | 2021-2022 | |
| Abbott Laboratories | $20.19 | 2021 | |
| Avanir Pharmaceuticals, INC. | $19.55 | 2021 | |
| Medtronic, INC. | $17.93 | 2022 | |
| Xeris Pharmaceuticals, INC. | $16.63 | 2021 | |
| Genentech USA, INC. | $15.14 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $13.35 | 2020 | |
| Sanofi-Aventis U.S. LLC | $11.36 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kyle Adams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.